Helus Pharma (HELP) closed at $7.67 on November 16, 2026, down 13.5% from the previous close, on volume of 6,473,419 shares (30-day average 1,411,472).
Data as of November 16, 2026.
16-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 21, 2026 | Call Spread | 18-Dec-2612.5 : 20 C | 10,014 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
TipRanks (Mon, 16-Nov 8:10 AM ET)
Helus Pharma Reports Positive Phase 3 HLP003 Results in Depression Study
TipRanks (Mon, 16-Nov 7:30 AM ET)
Helus Pharma Announces Scheduled Presentation of Phase 3 APPROACH Topline Results
TipRanks (Mon, 16-Nov 7:19 AM ET)
Helus Pharma Reports Fiscal Second-Quarter Results, APPROACH Enrollment Completion
TipRanks (Mon, 16-Nov 7:18 AM ET)
Market Chameleon (Mon, 16-Nov 2:05 AM ET)
Globe Newswire (Mon, 16-Nov 7:00 AM ET)
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Globe Newswire (Mon, 16-Nov 6:00 AM ET)
Globe Newswire (Sun, 15-Nov 12:00 PM ET)
Helus Pharma Files Interim Financial Statements for September 30, 2026
TipRanks (Fri, 13-Nov 5:02 PM ET)
Cybin GAAP EPS of -$1.41 misses by $0.68
Seeking Alpha News (Fri, 13-Nov 4:48 PM ET)
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Helus Pharma trades on the NASDAQ stock market under the symbol HELP.
As of November 16, 2026, HELP stock price declined to $7.67 with 6,473,419 million shares trading.
HELP has a beta of 2.34, meaning it tends to be more sensitive to market movements. HELP has a correlation of 0.12 to the broad based SPY ETF.
HELP has a market cap of $612.20 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that HELP belongs to (by Net Assets): PSIL, ONEQ, GWX, QQQS.
HELP support price is $8.41 and resistance is $9.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HELP shares will trade within this expected range on the day.